- Home
- QIPT vs AGEN Comparison
QIPT vs AGEN Comparison
Compare QIPT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- AGEN
- Stock Information
- Founded
- QIPT 1993
- AGEN 1994
- Country
- QIPT United States
- AGEN United States
- Employees
- QIPT N/A
- AGEN N/A
- Industry
- QIPT
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QIPT
- AGEN Health Care
- Exchange
- QIPT Nasdaq
- AGEN Nasdaq
- Market Cap
- QIPT 92.2M
- AGEN 87.7M
- IPO Year
- QIPT N/A
- AGEN 2000
- Fundamental
- Price
- QIPT $2.07
- AGEN $5.37
- Analyst Decision
- QIPT Buy
- AGEN Buy
- Analyst Count
- QIPT 2
- AGEN 4
- Target Price
- QIPT $2.85
- AGEN $13.00
- AVG Volume (30 Days)
- QIPT 2.6M
- AGEN 1.6M
- Earning Date
- QIPT 05-12-2025
- AGEN 05-12-2025
- Dividend Yield
- QIPT N/A
- AGEN N/A
- EPS Growth
- QIPT N/A
- AGEN N/A
- EPS
- QIPT N/A
- AGEN N/A
- Revenue
- QIPT $240,848,000.00
- AGEN $99,524,000.00
- Revenue This Year
- QIPT $3.35
- AGEN $14.49
- Revenue Next Year
- QIPT $5.39
- AGEN N/A
- P/E Ratio
- QIPT N/A
- AGEN N/A
- Revenue Growth
- QIPT N/A
- AGEN N/A
- 52 Week Low
- QIPT $1.35
- AGEN $1.38
- 52 Week High
- QIPT $4.07
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- QIPT 54.67
- AGEN 65.44
- Support Level
- QIPT $1.89
- AGEN $5.06
- Resistance Level
- QIPT $2.21
- AGEN $6.35
- Average True Range (ATR)
- QIPT 0.16
- AGEN 0.59
- MACD
- QIPT 0.05
- AGEN 0.16
- Stochastic Oscillator
- QIPT 73.58
- AGEN 71.18
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).